Article information
Full text is only aviable in PDF
References
[1.]
J.L. Skibba, J. Pinckley, E.F. Gilbert, R.O. Johnson.
Multiple primary melanoma following administration of levodopa.
Arch Pathol, 93 (1972), pp. 556-561
[2.]
K.H. Fiala, J. Whetteckey, B.V. Manyam.
Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?.
Parkinsonism Relat Dis, 9 (2003), pp. 321-327
[3.]
J.H. Olsen, S. Friis, K. Frederiksen.
Malignant melanoma and other types of cancer preceding Parkinson disease.
Epidemiology, 17 (2006), pp. 582-587
[4.]
J.H. Olsen, K. Tangerud, L. Wermuth, K. Frederiksen, S. Friis.
Treatment with levodopa and risk for malignant melanoma.
Mov Disord, 22 (2007), pp. 1252-1257
[5.]
Parkinson Study Group.
A randomized placebo-controlled trial of Rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Arch Neurol, 62 (2005), pp. 241-248
[6.]
R. Zanetti, D. Loria, S. Rosso.
Melanoma, Parkinson's disease and levodopa: casual or spurious link? A review of the literature.
Melanoma Res, 16 (2006), pp. 201-206
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
